Collegium Pharmaceutical Profit Margin

The latest profit margin for COLL is 5.93% as of June 2026. That compares with 5.13% in the prior-year period — up 15.6% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Collegium Pharmaceutical's historical trend and sector peers before judging valuation or financial health.

Over the past year, COLL's profit margin moved from 5.13% to 5.93% — a 15.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Collegium Pharmaceutical's valuation or profitability profile.

Against Healthcare companies, COLL currently prints 5.93% for profit margin, while the sector average sits near 13.89%. That is roughly 57.3% below the sector mean. Large gaps often invite a closer look at Collegium Pharmaceutical's growth, margins, and balance sheet.

Profit Margin shows how effectively Collegium Pharmaceutical converts resources into returns. At 5.93%, COLL may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 5.13% in the prior-year period — up 15.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting COLL's profit margin (5.93%), review year-over-year change from 5.13%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.